Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Effects of Pre-Surgical Ceralasertib or Olaparib in HNSCC
NCT03022409Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2017
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of ceralasertib and olaparib in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Conversion of an immunologically based 25-gene signature at Day 31. Started Sep 2017; status: completed.
02
Drugs
ceralasertibolaparib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03022409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03022409.